Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB fulfills the requirements for admission to trading of the company’s shares on the main market Nasdaq Stockholm. The first day

The company has announced that the first patient has been enrolled in the fimaChem RELEASE study with registration intent in inoperable bile duct cancer patients. The pivotal RELEASE study has

The company has submitted clinical trial authorization (CTA) application to initiate a Phase I study of its fully owned 4-1BB antibody ATOR-1017 for the treatment of metastasizing cancer. ATOR-1017 is

The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with

Data from the company’s Phase 1/2 O-12-M1 clinical study of lead candidate melflufen demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated

The company has entered a non-binding term-sheet with STADA Arzneimittel for cooperation regarding sales and marketing of Spherotide for Europe, and furthermore, the company updates on its plans to take

The company has completed treatment of 25% of patients in the STAR trial of its medical device, SiPore15, and is well on track to finalize results by Q4 of this

The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years.  Few companies can take the hit of investing hundreds

The Board of Directors of the Finnish biotech company FIT Biotech has decided to file an application for bankruptcy, reports Huvudstadsbladet. The reason behind the decision is that a financing

The company reports that a collaboration agreement with the Centre for Skin Sciences (CSS) at University of Bradford, UK, has been signed. The aim is to combine in vitro experiments with the